|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 264.48 USD | +1.62% |
|
-2.08% | -12.95% |
| 12/06 | BeOne Says Updated Results for Cancer Drug Tacabrutideg Show 'Durable' Responses | MT |
| 12/06 | Beone Medicines AG Approves Board and Committee Elections | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -12.64 | -15.01 | -12.4 | -6.07 | 3.96 | |||||
Return on Total Capital | -15.84 | -18.96 | -15.99 | -8.01 | 5.66 | |||||
Return On Equity % | -27.95 | -38.11 | -22.26 | -18.77 | 7.46 | |||||
Return on Common Equity | -27.95 | -38.11 | -22.26 | -18.77 | 7.46 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | -38.07 | -36.09 | 84.55 | 84.41 | 87.49 | |||||
SG&A Margin | 84.31 | 90.31 | 61.22 | 48.08 | 38.96 | |||||
EBITDA Margin % | -118.58 | -122 | -45.74 | -10.55 | 10.83 | |||||
EBITA Margin % | -122.38 | -126.4 | -49.01 | -14.93 | 8.37 | |||||
EBIT Margin % | -122.44 | -126.45 | -49.15 | -14.93 | 8.37 | |||||
Income From Continuing Operations Margin % | -120.15 | -141.52 | -35.86 | -16.92 | 5.37 | |||||
Net Income Margin % | -120.15 | -141.52 | -35.86 | -16.92 | 5.37 | |||||
Net Avail. For Common Margin % | -120.15 | -141.52 | -35.86 | -16.92 | 5.37 | |||||
Normalized Net Income Margin | -76.93 | -85.23 | -30.04 | -8.6 | 5.57 | |||||
Levered Free Cash Flow Margin | -102.69 | -66.58 | -51.71 | -9.63 | 13.33 | |||||
Unlevered Free Cash Flow Margin | -101.19 | -65.73 | -51.6 | -9.39 | 14.01 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.17 | 0.19 | 0.4 | 0.65 | 0.76 | |||||
Fixed Assets Turnover | 2.04 | 1.7 | 2.07 | 2.43 | 3.05 | |||||
Receivables Turnover (Average Receivables) | 4.33 | 4.31 | 9.26 | 7.37 | 6.85 | |||||
Inventory Turnover (Average Inventory) | 9.79 | 7.34 | 1.09 | 1.3 | 1.21 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 4.76 | 3.55 | 2.32 | 1.8 | 3.41 | |||||
Quick Ratio | 4.45 | 3.22 | 1.97 | 1.51 | 2.97 | |||||
Operating Cash Flow to Current Liabilities | -0.81 | -1.02 | -0.64 | -0.06 | 0.62 | |||||
Days Sales Outstanding (Average Receivables) | 84.33 | 84.59 | 39.43 | 49.68 | 53.25 | |||||
Days Outstanding Inventory (Average Inventory) | 37.3 | 49.72 | 335.52 | 280.65 | 301.16 | |||||
Average Days Payable Outstanding | 50.76 | 51.7 | 216.68 | 195.82 | 206.37 | |||||
Cash Conversion Cycle (Average Days) | 70.87 | 82.6 | 158.27 | 134.51 | 148.04 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 11.13 | 13.61 | 26.3 | 32.41 | 25.06 | |||||
Total Debt / Total Capital | 10.01 | 11.98 | 20.82 | 24.48 | 20.04 | |||||
LT Debt/Equity | 3.93 | 5.56 | 6.22 | 6.32 | 23.27 | |||||
Long-Term Debt / Total Capital | 3.53 | 4.89 | 4.92 | 4.78 | 18.61 | |||||
Total Liabilities / Total Assets | 27.79 | 31.29 | 39.07 | 43.72 | 46.74 | |||||
EBIT / Interest Expense | -51.06 | -93.72 | -285.78 | -38.61 | 7.68 | |||||
EBITDA / Interest Expense | -48.41 | -88.63 | -257.94 | -24.97 | 10.47 | |||||
(EBITDA - Capex) / Interest Expense | -57.73 | -105.67 | -390.81 | -58.4 | 7.28 | |||||
Total Debt / EBITDA | -0.51 | -0.35 | -0.85 | -2.94 | 1.79 | |||||
Net Debt / EBITDA | 4.34 | 2.33 | 2.06 | 4.21 | -5.67 | |||||
Total Debt / (EBITDA - Capex) | -0.43 | -0.3 | -0.56 | -1.25 | 2.58 | |||||
Net Debt / (EBITDA - Capex) | 3.64 | 1.95 | 1.36 | 1.8 | -8.15 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 280.83 | 20.37 | 73.65 | 54.96 | 40.23 | |||||
Gross Profit, 1 Yr. Growth % | -57.62 | 14.11 | 84.06 | 54.71 | 45.34 | |||||
EBITDA, 1 Yr. Growth % | -14.21 | 23.85 | -34.9 | -64.26 | -244.28 | |||||
EBITA, 1 Yr. Growth % | -13.12 | 24.33 | -32.67 | -52.79 | -178.72 | |||||
EBIT, 1 Yr. Growth % | -13.11 | 24.31 | -32.5 | -52.92 | -178.69 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -11.69 | 37.45 | -56 | -26.87 | -144.5 | |||||
Net Income, 1 Yr. Growth % | -11.49 | 37.45 | -56 | -26.87 | -144.5 | |||||
Normalized Net Income, 1 Yr. Growth % | -11.43 | 33.36 | -38.95 | -55.66 | -190.9 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -20.38 | 23.66 | -56.53 | -27.5 | -140.33 | |||||
Accounts Receivable, 1 Yr. Growth % | 699.82 | -64.16 | 106.75 | 88.89 | 27.92 | |||||
Inventory, 1 Yr. Growth % | 171.72 | 16.37 | 47.38 | 18.95 | 22.88 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 57.28 | 35.58 | 48.48 | 21.02 | 4.2 | |||||
Total Assets, 1 Yr. Growth % | 54.37 | -25.26 | -9 | 1.99 | 38.3 | |||||
Tangible Book Value, 1 Yr. Growth % | 60.35 | -28.64 | -19.86 | -5.72 | 31.01 | |||||
Common Equity, 1 Yr. Growth % | 61.35 | -28.52 | -19.3 | -5.8 | 30.88 | |||||
Cash From Operations, 1 Yr. Growth % | 1.19 | 15.24 | -22.66 | -87.85 | -901.8 | |||||
Capital Expenditures, 1 Yr. Growth % | 123.77 | 23.77 | 72.66 | -12.32 | -62.28 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 60.57 | -21.77 | 34.66 | -71.19 | -292.03 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 60.62 | -21.61 | 36.1 | -71.86 | -309.54 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 65.74 | 114.11 | 44.58 | 64.04 | 47.41 | |||||
Gross Profit, 2 Yr. CAGR % | -11.38 | -30.45 | 43.37 | 68.75 | 49.95 | |||||
EBITDA, 2 Yr. CAGR % | 21.73 | 3.08 | -10.16 | -51.75 | -28.23 | |||||
EBITA, 2 Yr. CAGR % | 22.55 | 3.93 | -8.46 | -43.61 | -39.06 | |||||
EBIT, 2 Yr. CAGR % | 22.49 | 3.93 | -8.35 | -43.61 | -39.15 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 21.94 | 10.92 | -22.23 | -43.27 | -42.95 | |||||
Net Income, 2 Yr. CAGR % | 22.06 | 11.05 | -22.23 | -43.27 | -42.95 | |||||
Normalized Net Income, 2 Yr. CAGR % | 24.08 | 9.01 | -9.65 | -47.97 | -36.51 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -1.8 | -0.1 | -26.68 | -43.86 | -45.93 | |||||
Accounts Receivable, 2 Yr. CAGR % | 161.08 | 69.32 | -13.91 | 97.62 | 55.44 | |||||
Inventory, 2 Yr. CAGR % | 191.5 | 77.82 | 30.96 | 32.41 | 20.9 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 47.3 | 46.03 | 41.89 | 34.05 | 12.3 | |||||
Total Assets, 2 Yr. CAGR % | 131.57 | 6.72 | -17.53 | -3.66 | 18.77 | |||||
Tangible Book Value, 2 Yr. CAGR % | 154.55 | 6.01 | -24.38 | -13.08 | 11.14 | |||||
Common Equity, 2 Yr. CAGR % | 154.72 | 6.44 | -24.05 | -12.81 | 11.04 | |||||
Cash From Operations, 2 Yr. CAGR % | 31.57 | 7.99 | -5.6 | -69.35 | -1.3 | |||||
Capital Expenditures, 2 Yr. CAGR % | 71.3 | 66.42 | 46.18 | 23.04 | -42.49 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 44.56 | 11.94 | 2.76 | -37.64 | -25.22 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 44.31 | 12.07 | 3.42 | -38.03 | -23.25 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 81.05 | 48.98 | 99.67 | 47.96 | 55.69 | |||||
Gross Profit, 3 Yr. CAGR % | -4.21 | -3.59 | 25.3 | 47.05 | 60.55 | |||||
EBITDA, 3 Yr. CAGR % | 26.11 | 22.43 | -11.56 | -33.92 | -30.53 | |||||
EBITA, 3 Yr. CAGR % | 26.9 | 23.14 | -10.07 | -26.59 | -37.01 | |||||
EBIT, 3 Yr. CAGR % | 26.84 | 23.1 | -10 | -26.6 | -37.02 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 27.99 | 28.22 | -18.5 | -23.81 | -47.68 | |||||
Net Income, 3 Yr. CAGR % | 28.01 | 28.31 | -18.44 | -23.81 | -47.68 | |||||
Normalized Net Income, 3 Yr. CAGR % | 28.06 | 27.1 | -10.07 | -28.73 | -37.34 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 7.82 | 7.14 | -24.3 | -26.95 | -49.72 | |||||
Accounts Receivable, 3 Yr. CAGR % | 113.46 | 34.68 | 80.98 | 11.86 | 70.95 | |||||
Inventory, 3 Yr. CAGR % | 146.28 | 114.64 | 67.03 | 26.83 | 29.15 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 64.96 | 43.29 | 46.84 | 34.56 | 23.25 | |||||
Total Assets, 3 Yr. CAGR % | 56.64 | 58.16 | 1.2 | -11.48 | 8.68 | |||||
Tangible Book Value, 3 Yr. CAGR % | 54.29 | 65.6 | -3.43 | -18.61 | -0.34 | |||||
Common Equity, 3 Yr. CAGR % | 53.11 | 65.77 | -2.95 | -18.4 | -0.17 | |||||
Cash From Operations, 3 Yr. CAGR % | 33.35 | 25.88 | -3.39 | -52.34 | -9.01 | |||||
Capital Expenditures, 3 Yr. CAGR % | 55.24 | 53.71 | 68.47 | 23.28 | -17.04 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 36.04 | 17.71 | 19.12 | -32.7 | -8.95 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 35.93 | 17.65 | 19.63 | -32.94 | -7.03 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 305.72 | 42.81 | 65.47 | 54.83 | 76.85 | |||||
Gross Profit, 5 Yr. CAGR % | 35.8 | 70.37 | 32.48 | 41.33 | 34.64 | |||||
EBITDA, 5 Yr. CAGR % | 64.68 | 79.12 | 10.09 | -15.65 | -18.66 | |||||
EBITA, 5 Yr. CAGR % | 65.18 | 78.76 | 11.34 | -9.91 | -23.04 | |||||
EBIT, 5 Yr. CAGR % | 65.2 | 78.63 | 11.36 | -9.93 | -23.05 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 63.98 | 84.67 | 5.52 | -7.47 | -29.34 | |||||
Net Income, 5 Yr. CAGR % | 63.98 | 84.75 | 5.53 | -7.43 | -29.31 | |||||
Normalized Net Income, 5 Yr. CAGR % | 65.18 | 84.32 | 11.38 | -11.04 | -21.76 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 31.73 | 54.2 | -7.02 | -17.26 | -33.83 | |||||
Accounts Receivable, 5 Yr. CAGR % | - | 42.54 | 48.45 | 57.01 | 70.29 | |||||
Inventory, 5 Yr. CAGR % | - | 91.62 | 91.3 | 76.92 | 46.77 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 93.52 | 72.51 | 55.31 | 39.52 | 31.9 | |||||
Total Assets, 5 Yr. CAGR % | 84.37 | 43.55 | 20.88 | 29.71 | 7.89 | |||||
Tangible Book Value, 5 Yr. CAGR % | 77.38 | 46.21 | 15.59 | 27.96 | 2.15 | |||||
Common Equity, 5 Yr. CAGR % | 77.64 | 45.6 | 15.26 | 28.2 | 2.42 | |||||
Cash From Operations, 5 Yr. CAGR % | 70.74 | 159.36 | 16.14 | -28.46 | -2.56 | |||||
Capital Expenditures, 5 Yr. CAGR % | 62.09 | 47.65 | 51.55 | 40.62 | 9.6 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 76.45 | 86.42 | 21.52 | -8.68 | -1.09 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 76.2 | 90.92 | 21.77 | -8.94 | 0.2 |
- Stock Market
- Stocks
- ONC Stock
- Financials BeOne Medicines AG
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















